The vascular imaging market size is expected to increase from USD 7.32 billion in 2025 to USD 7.78 billion in 2026 and reach USD 10.80 billion by 2031, growing at a CAGR of 6.77% over 2026-2031. This report is Segmented by Modality (Ultrasound/Doppler, CTA, X-Ray Angiography/DSA, and More), Procedure Type (Coronary Angiography/PCI, Peripheral Arterial, Neurovascular, and More), Application (Atherosclerosis/CAD & PAD, Aneurysmal Disorders, and More), End User (Hospitals, Diagnostic Centers, and More), and Geography (North America, and More). Market Forecasts are Provided in Terms of Value (USD).
Other drivers and restraints analyzed in the detailed report include:
The vascular imaging market share for computed-tomography angiography reached a significant percentage share in 2025 and rises in tandem with AI reconstruction, while X-ray angiography benefits from hybrid-OR demand that pairs ceiling C-arms with 3D fusion software. Magnetic resonance angiography consolidates difficult renal and carotid cohorts, and nuclear medicine retains a research niche below a 5% revenue threshold.
Aortic and aneurysm imaging grows 8.65% annually as TEVAR treatment windows widen and cone-beam CT fusion lowers contrast burden 30%-40%. Coronary angiography maintains dominant revenue owing to 5,000 U.S. cath labs and guideline-mandated IVUS/OCT for complex PCI. Peripheral arterial angiography accelerates on new PAD screening recommendations, while neurovascular guidance benefits from 24-hour thrombectomy eligibility and AI triage that cuts door-to-groin time to 58 minutes.
Single-stage EVAR enabled by intraoperative cone-beam CT reduces 30-day readmissions from 8.4% to 2.9% and illustrates the cost-avoidance case sustaining scanner replacement cycles. Deep-vein-thrombosis imaging gains consistency as CTPA risk-stratification routines enter every emergency department, bolstering vascular imaging market depth.
Asia-Pacific delivers the fastest regional CAGR at 9.12%, driven by China’s CNY 1 trillion (USD 0.15 trillion) hospital build-out and India’s Production-Linked Incentive that subsidizes domestic CT and ultrasound manufacturing. United Imaging captured 18% of new CT installs in tier-1 Chinese cities by Q4 2024 after pricing photon-counting systems 25% below incumbents. Japan lifted the OCT reimbursement 56%, reinforcing premium adoption curves.
Europe’s significant share faces MDR/IVDR attrition that places 40% of legacy devices at withdrawal risk and lifts compliance cost 30%, favoring vendors with deep notified-body ties. The Middle East and Africa grow off a small base, Saudi Arabia’s USD 64 billion Vision 2030 spend anchors GCC demand and delivered the region’s first photon-counting CT in June 2024. South America’s 5% share is steady, with Brazil and Argentina adopting refurbished angiography systems to offset currency volatility.
Global Vascular Imaging Market Trends and Insights
CVD and PAD Burden Elevates Demand for Vascular Diagnostics and Monitoring
Concerted guideline updates now mandate ankle-brachial index screening for adults over 65 and duplex or CT angiography for symptomatic peripheral arterial disease, effectively doubling the diagnostic pool worldwide. European recommendations position pre-intervention CTA or MRA as compulsory for chronic limb-threatening ischemia, embedding imaging into every revascularization workflow. Serial carotid duplex reimbursements in Japan and South Korea establish recurring revenue that was previously episodic. Cumulative procedure growth maintains a clear pull on the vascular imaging market even as modality pricing edges downward.Shift Toward Minimally Invasive Endovascular Procedures Increases Intraprocedural Imaging Volumes
Endovascular aneurysm repair now addresses roughly 80% of abdominal cases and thoracic EVAR treats up to 80% of type B dissections, each case requiring triple-phase imaging, pre-operative CTA, cone-beam CT fusion, and completion angiography. Complex PCI volumes climbed 12% year-over-year in 2024, while randomized evidence shows OCT guidance lowers target-vessel failure by 28%, driving guideline elevation of intravascular imaging. Hybrid operating rooms surpassed 1,200 installs in North America by late 2025 and cut contrast volume 30%-40% per EVAR, expanding utilization. These intraprocedural needs power resilient spending within the vascular imaging market despite capital-budget scrutiny.Technologist Shortages Cap Scanning Capacity and Extend Wait Times
Vacancy rates reached 19.4% for CT technologists and 17.4% for cardiovascular interventional roles in 2025, lengthening median hiring time to 94 days and delaying scanner purchases. European radiographer deficits hit 12,000 positions in 2024, with Brexit-related workforce exits worsening U.K. aortic-imaging queues. Cross-training sonographers and deploying AI auto-positioning offers only partial relief, underscoring a human-capital ceiling on the vascular imaging market.Other drivers and restraints analyzed in the detailed report include:
- CT, Ultrasound, and AI Advances Improve Diagnostic Yield and Throughput in Vascular Pathways
- Reimbursement Tailwinds for CCTA + FFR-CT and Intravascular Imaging Codes Accelerate Adoption
- Radiation Dose and Iodinated Contrast Safety/Availability Concerns Limit CT and Angiography Use
Segment Analysis
Intravascular imaging is forecast to post the fastest modality expansion at 8.22% CAGR as Abbott’s Ultreon 3.0 and Conavi’s hybrid IVUS-OCT automate lumen analytics and cut interpretation time 35%. The vascular imaging market size for ultrasound commanded 40.24% share in 2025 and still drives point-of-care adoption, but capital intensity is pivoting to photon-counting CT where vendors promise 0.2 mm resolution and dual‐energy subtraction. Ultrasound’s portability and zero radiation sustain 5.8% annual growth, yet margin migration to premium CT and angiography systems is unmistakable.The vascular imaging market share for computed-tomography angiography reached a significant percentage share in 2025 and rises in tandem with AI reconstruction, while X-ray angiography benefits from hybrid-OR demand that pairs ceiling C-arms with 3D fusion software. Magnetic resonance angiography consolidates difficult renal and carotid cohorts, and nuclear medicine retains a research niche below a 5% revenue threshold.
Aortic and aneurysm imaging grows 8.65% annually as TEVAR treatment windows widen and cone-beam CT fusion lowers contrast burden 30%-40%. Coronary angiography maintains dominant revenue owing to 5,000 U.S. cath labs and guideline-mandated IVUS/OCT for complex PCI. Peripheral arterial angiography accelerates on new PAD screening recommendations, while neurovascular guidance benefits from 24-hour thrombectomy eligibility and AI triage that cuts door-to-groin time to 58 minutes.
Single-stage EVAR enabled by intraoperative cone-beam CT reduces 30-day readmissions from 8.4% to 2.9% and illustrates the cost-avoidance case sustaining scanner replacement cycles. Deep-vein-thrombosis imaging gains consistency as CTPA risk-stratification routines enter every emergency department, bolstering vascular imaging market depth.
Complete Report Scope:
- By Modality
- Ultrasound / Doppler
- Computed Tomography Angiography (CTA)
- X-ray Angiography / Digital Subtraction Angiography (DSA)
- Magnetic Resonance Angiography (MRA)
- Intravascular Imaging (IVUS / OCT / NIRS)
- Nuclear Medicine (SPECT / PET vascular applications)
- By Procedure Type
- Coronary angiography / PCI guidance
- Peripheral arterial angiography & interventions (lower/upper extremity)
- Neurovascular angiography & EVT guidance
- Aortic/EVAR/TEVAR imaging
- Venous thromboembolism imaging (DVT/PE pathways)
- Carotid and cerebrovascular duplex/CTA/MRA
- By Application
- Atherosclerosis / CAD & PAD
- Aneurysmal disorders
- Vasculitis & large-vessel inflammation
- Deep vein thrombosis & pulmonary embolism
- Arteriovenous malformations & fistulas
- Tumor vascularity and pre-op planning
- By End User
- Hospitals (Tertiary/Community)
- Diagnostic Imaging Centers
- Ambulatory Surgery Centers
- Academic & Research Institutes
- By Geography
- North America
- United States
- Canada
- Mexico
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- China
- India
- Japan
- South Korea
- Australia
- Rest of Asia-Pacific
- Middle East and Africa
- GCC
- South Africa
- Rest of Middle East and Africa
- South America
- Brazil
- Argentina
- Rest of South America
- North America
Geography Analysis
North America controls 39.35% of 2025 revenue thanks to 1,200 hybrid ORs, early FFR-CT reimbursement, and an installed base exceeding 5,000 cath labs. Yet technologist vacancies lengthen elective CTA wait times from 12 days in 2023 to 18 days in 2025, creating latent demand buffered by AI workflow tools.Asia-Pacific delivers the fastest regional CAGR at 9.12%, driven by China’s CNY 1 trillion (USD 0.15 trillion) hospital build-out and India’s Production-Linked Incentive that subsidizes domestic CT and ultrasound manufacturing. United Imaging captured 18% of new CT installs in tier-1 Chinese cities by Q4 2024 after pricing photon-counting systems 25% below incumbents. Japan lifted the OCT reimbursement 56%, reinforcing premium adoption curves.
Europe’s significant share faces MDR/IVDR attrition that places 40% of legacy devices at withdrawal risk and lifts compliance cost 30%, favoring vendors with deep notified-body ties. The Middle East and Africa grow off a small base, Saudi Arabia’s USD 64 billion Vision 2030 spend anchors GCC demand and delivered the region’s first photon-counting CT in June 2024. South America’s 5% share is steady, with Brazil and Argentina adopting refurbished angiography systems to offset currency volatility.
List of Companies Covered in this Report:
- Abbott Laboratories
- Boston Scientific
- Bracco
- Canon
- Conavi Medical
- Esaote
- FUJIFILM (SonoSite)
- GE Healthcare
- Guerbet
- Infraredx (a Nipro Company)
- Koninklijke Philips (Philips Healthcare)
- Mindray
- Samsung Group
- Shimadzu
- Siemens Healthineers
- Terumo
- United Imaging Healthcare
- Ziehm Imaging
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
Table of Contents
1 Introduction
4 Market Landscape
5 Market Size & Growth Forecasts (Value, USD)
6 Competitive Landscape
7 Market Opportunities & Future Outlook
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Abbott Laboratories
- Boston Scientific
- Bracco Imaging
- Canon Medical Systems
- Conavi Medical
- Esaote
- FUJIFILM (SonoSite)
- GE HealthCare
- Guerbet
- Infraredx (a Nipro Company)
- Koninklijke Philips (Philips Healthcare)
- Mindray
- Samsung Medison
- Shimadzu Corporation
- Siemens Healthineers
- Terumo
- United Imaging Healthcare
- Ziehm Imaging
